Open AccessPeculiarities of community-acquired pneumonia treatment in patients with COVID-19
Author(s) -
Carolina Catcov,
Svetlana Chislaru,
Ina Pogonea,
Nicolae Bacinschi
Publication year - 2021
Publication title -
buletinul academiei de ştiinţe a moldovei: ştiinţe medicale
Language(s) - English
Resource type - Journals
ISSN - 1857-0011
DOI - 10.52692/1857-0011.2021.1-69.22
Subject(s) - medicine , cephalosporin , pneumonia , leukocytosis , sputum , chlamydophila pneumoniae , chlamydia , azithromycin , community acquired pneumonia , antibiotics , atypical pneumonia , microbiology and biotechnology , immunology , chlamydiaceae , biology , tuberculosis , pathology
The clinical picture (fever, cough, sputum, auscultatory changes), peripheral blood parameters (leukocytosis, ESR) and radiological data are currently the criteria for suspecting bacterial pneumonia in patients with SARS CoV-2 infection and for indication of antibacterial treatment. The initiation of antibiotic therapy is empirical by taking into account the pathogens most likely involved in community-acquired pneumonia (Str pneumoniae, St. aureus, Kl. pneumoniae, Haemofillus influenzae, Mecoplasma pneumoniae, Chlamydia, Ps. aeruginosa). Beta-lactams (cephalosporins, carbapenems), protected beta-lactams, macrolides and fluoroquinolones are the most commonly administered groups, and the combinations of cephalosporins + macrolides and cephalosporins + fluoroquinolones constitute the most used groups of antibacterial treatment in order to include bacterial flora, gram-positive or gram-negative, and atypical.